SCHEMBL6282030

SCHEMBL6282030

O=C(O)CN1C(=O)N(C(=O)c2ccc3ccccc3c2)C(c2ccccc2)(c2ccccc2)C1=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
NPC1 O15118 1/20 0.39
TSHR P16473 2/20 0.39
LMNA P02545 1/20 0.39
DRD4 P21917 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
HPGD P15428 1/20 0.38
AKR1B1 P15121 1/20 0.38
HDAC6 Q9UBN7 1/20 0.37
BCHE P06276 1/20 0.37
AKR1C1 Q04828 1/20 0.37
ENPP3 O14638 1/20 0.37
ALPL P05186 1/20 0.37
XIAP P98170 1/20 0.37
PTPN1 P18031 1/20 0.37
CYP1B1 Q16678 1/20 0.36
NR1H4 Q96RI1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282035 0.79 BCHE (0.42) KMT2ANPC1TSHRLMNADRD4
SCHEMBL6284071 0.76 TSHR (0.45) KMT2ANPC1TSHRLMNACES2
SCHEMBL6282913 0.72 KMT2A (0.46) KMT2ANPC1TSHRLMNADRD4
SCHEMBL6287762 0.72 BCHE (0.41) KMT2ANPC1TSHRLMNADRD4
SCHEMBL6284743 0.72 TSHR (0.46) KMT2ANPC1TSHRLMNADRD4
SCHEMBL6283118 0.71 NPC1 (0.49) NPC1TSHRLMNADRD4CES2
SCHEMBL6282090 0.70 KMT2A (0.46) KMT2ANPC1TSHRLMNADRD4
SCHEMBL6282939 0.69 BCHE (0.40) KMT2ANPC1TSHRLMNADRD4
SCHEMBL6287739 0.68 TSHR (0.39) KMT2ATSHRHPGDBCHEENPP3
SCHEMBL6285233 0.68 TSHR (0.44) KMT2ANPC1TSHRLMNACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919365-B2 Imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-07-19 US disclosed
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1384715-A1 NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS Senju Pharmaceutical Co., Ltd. (JP) 2004-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs CMA1, TPSD1, TPSB2 KMT2A 2938/4885NPC1 1028/4885TSHR 1021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.